Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®)
Scilex Holding Company (Nasdaq: SCLX), a revenue-generating company focused on non-opioid pain management products, has received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®). This accreditation confirms that Scilex has met all the drug distributor criteria established by NABP, a nonprofit organization founded in 1904 that works with state pharmacy boards to support patient and prescription drug safety.
NABP's activities include conducting examinations to assess pharmacist competency, facilitating pharmacist licensure transfer, providing verification services, and overseeing various pharmacy accreditation programs. This accreditation is a significant milestone for Scilex, potentially enhancing its credibility in the pharmaceutical distribution sector.
Scilex Holding Company (Nasdaq: SCLX), un'azienda generatrice di entrate focalizzata su prodotti per la gestione del dolore non oppiacei, ha ricevuto l'Accreditamento per Distributori di Farmaci dalla National Association of Boards of Pharmacy® (NABP®). Questo accreditamento conferma che Scilex ha soddisfatto tutti i criteri stabiliti da NABP, un'organizzazione nonprofit fondata nel 1904 che collabora con i consigli statali di farmacia per sostenere la sicurezza dei pazienti e dei farmaci prescritti.
Le attività della NABP includono la conduzione di esami per valutare le competenze dei farmacisti, facilitare il trasferimento delle licenze dei farmacisti, fornire servizi di verifica e supervisionare vari programmi di accreditamento della farmacia. Questo accreditamento rappresenta una pietra miliare significativa per Scilex, potenzialmente migliorando la sua credibilità nel settore della distribuzione farmaceutica.
Scilex Holding Company (Nasdaq: SCLX), una empresa generadora de ingresos enfocada en productos de manejo del dolor no opioides, ha recibido la Acreditación de Distribuidor de Medicamentos de la National Association of Boards of Pharmacy® (NABP®). Esta acreditación confirma que Scilex ha cumplido con todos los criterios de distribuidor de medicamentos establecidos por NABP, una organización sin fines de lucro fundada en 1904 que trabaja con las juntas estatales de farmacia para apoyar la seguridad de los pacientes y de los medicamentos recetados.
Las actividades de la NABP incluyen la realización de exámenes para evaluar la competencia de los farmacéuticos, facilitar la transferencia de licencias de farmacéuticos, proporcionar servicios de verificación y supervisar varios programas de acreditación farmacéutica. Esta acreditación es un hito significativo para Scilex, que potencialmente mejora su credibilidad en el sector de distribución farmacéutica.
Scilex Holding Company (Nasdaq: SCLX)는 비오피오이드 통증 관리 제품에 초점을 맞춘 수익 창출 기업으로, National Association of Boards of Pharmacy® (NABP®)로부터 약품 유통업체 인증을 받았습니다. 이 인증은 Scilex가 NABP가 수립한 모든 약품 유통업체 기준을 충족했음을 확인합니다. NABP는 1904년에 설립된 비영리 조직으로, 주 주약사 위원회와 협력하여 환자 및 처방약의 안전을 지원합니다.
NABP의 활동에는 약사의 역량을 평가하기 위한 시험 실시, 약사 면허 이전 지원, 검증 서비스 제공, 다양한 약국 인증 프로그램 감독 등이 포함됩니다. 이 인증은 Scilex에게 중요한 이정표가 되며, 제약 유통 분야에서의 신뢰성을 향상시킬 수 있습니다.
Scilex Holding Company (Nasdaq: SCLX), une entreprise générant des revenus axée sur des produits de gestion de la douleur non opioïdes, a reçu l'Accréditation de Distributeur de Médicaments de la National Association of Boards of Pharmacy® (NABP®). Cette accréditation confirme que Scilex a satisfait à tous les critères de distributeur de médicaments établis par la NABP, une organisation à but non lucratif fondée en 1904 qui collabore avec les conseils pharmaceutiques des États pour soutenir la sécurité des patients et des médicaments prescrits.
Les activités de la NABP incluent la réalisation d'examens pour évaluer les compétences des pharmaciens, faciliter le transfert de licences de pharmaciens, fournir des services de vérification et superviser divers programmes d'accréditation pharmaceutique. Cette accréditation représente une étape importante pour Scilex, améliorant potentiellement sa crédibilité dans le secteur de la distribution pharmaceutique.
Die Scilex Holding Company (Nasdaq: SCLX) ist ein umsatzgenerierendes Unternehmen, das sich auf nicht-opioidhaltige Schmerzmanagementprodukte konzentriert und hat die Zertifizierung als Arzneimittelvertrieb von der National Association of Boards of Pharmacy® (NABP®) erhalten. Diese Zertifizierung bestätigt, dass Scilex alle von der NABP festgelegten Kriterien für Arzneimittelvertrieb erfüllt hat. Die NABP ist eine gemeinnützige Organisation, die 1904 gegründet wurde und mit den staatlichen Apothekenbehörden zusammenarbeitet, um die Sicherheit von Patienten und verschreibungspflichtigen Medikamenten zu unterstützen.
Zu den Aktivitäten der NABP gehören die Durchführung von Prüfungen zur Bewertung der Kompetenz von Apothekern, die Erleichterung des Lizenztransferprozesses für Apotheker, die Bereitstellung von Verifizierungsdiensten und die Überwachung verschiedener Apothekenakkreditierungsprogramme. Diese Zertifizierung ist ein bedeutender Meilenstein für Scilex und könnte deren Glaubwürdigkeit im Pharmavertrieb stärken.
- Received Drug Distributor Accreditation from NABP
- Meets all drug distributor criteria set by NABP
- Potential enhancement of credibility in pharmaceutical distribution
- None.
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®). Scilex has satisfied all the drug distributor criteria set in place by the NABP.
The NABP® is a 501(c)(3) nonprofit organization founded in 1904. Working with their members – the state boards of pharmacy – they help support patient and prescription drug safety, through examinations that assess pharmacist competency, pharmacist licensure transfer and verification services, and various pharmacy accreditation programs.
For more information on Scilex Holding Company, refer to www.scilexholding.com
For more information on Semnur Pharmaceuticals, refer to www.semnurpharma.com
For more information on Scilex Holding Company Sustainability Report, refer to www.scilexholding.com/investors/sustainability
For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.
For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.
For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.
https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
About Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system)
In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system)
Scilex Holding Company is headquartered in Palo Alto, California.
Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Scilex’s long-term objectives and commercialization plans, future opportunities for Scilex, Scilex’s future business strategies and Scilex’s current and prospective product candidates.
Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the unpredictability of trading markets; general economic, political and business conditions; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.
Contacts:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website: www.scilexholding.com
SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.
Gloperba® is the subject of an exclusive, transferable license to Scilex Holding Company to use the registered trademark.
ELYXYB® is a registered trademark owned by Scilex Holding Company.
All other trademarks are the property of their respective owners.
© 2024 Scilex Holding Company All Rights Reserved.
FAQ
What accreditation did Scilex Holding Company (SCLX) receive on September 12, 2024?
What does the Drug Distributor Accreditation from NABP signify for Scilex (SCLX)?
What is Scilex Holding Company's (SCLX) primary business focus?
What is the National Association of Boards of Pharmacy® (NABP®) and what does it do?
